• Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Effective Altruism Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Global Health R&D
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth (Longtermism)
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Contact Us
    • Stay Updated
  • We’re hiring!
  • Focus Areas
    • Cause Selection
    • Global Health & Wellbeing
      • Effective Altruism Community Growth (Global Health and Wellbeing)
      • Farm Animal Welfare
      • Global Aid Policy
      • Global Health & Development
      • Global Health R&D
      • Scientific Research
      • South Asian Air Quality
    • Longtermism
      • Biosecurity & Pandemic Preparedness
      • Effective Altruism Community Growth (Longtermism)
      • Potential Risks from Advanced AI
    • Other Areas
      • Criminal Justice Reform
      • History of Philanthropy
      • Immigration Policy
      • Land Use Reform
      • Macroeconomic Stabilization Policy
  • Grants
  • Research & Updates
    • Research Reports
    • Blog Posts
    • Notable Lessons
    • In the News
  • About Us
    • Grantmaking Process
    • How to Apply for Funding
    • Team
    • Contact Us
    • Stay Updated
  • We’re hiring!

Kainomyx — Antimalarial Drug (2021)

Visit Grantee Site
  • Portfolio Area: Other Scientific Research Areas
  • Organization Name: Kainomyx
  • Amount: $4,000,000

  • Award Date: September 2021

Table of Contents

    Open Philanthropy recommended an investment of $4,000,000 in Kainomyx to develop and produce new drugs to treat malaria and other parasitic diseases, such as cryptosporidiosis and toxoplasmosis. If effective, the new drugs would act by inhibiting cytoskeletal proteins in malarial and other parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing resistance to existing treatments.

    This follows our May 2020 investment and falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.

    Related Items

    • Other Scientific Research Areas

      National Bureau of Economic Research — Innovation Policy Working Group

      Open Philanthropy recommended a grant of $467,500 over two years to the National Bureau of Economic Research (NBER) to support its Innovation Policy Working Group, led by Professors...

      Read more
    • Other Scientific Research Areas

      University of Washington — Universal Influenza Vaccines (Neil King)

      Open Philanthropy recommended a grant of $3,230,394 over five years to the University of Washington to support work led by Dr. Neil King on the development of universal...

      Read more
    • Other Scientific Research Areas

      UCSF — Chronic Pain Research (Allan Basbaum) (2021)

      Open Philanthropy recommended a grant of $1,066,312 over three years to the University of California, San Francisco (UCSF), to continue to support basic research, led by Allan Basbaum,...

      Read more
    Back to Grants Database
    Open Philanthropy
    Open Philanthropy
    • Careers
    • Press Kit
    • Governance
    • Privacy Policy
    • Stay Updated
    Mailing Address
    Open Philanthropy
    182 Howard Street #225
    San Francisco, CA 94105
    Email
    [email protected]
    Media Inquiries
    [email protected]
    Anonymous Feedback
    Feedback Form

    © Open Philanthropy 2022 Except where otherwise noted, this work is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License. If you'd like to translate this content into another language, please get in touch!